Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23905132 | 0.87 | LTA4H (0.64) | KEAP1NFE2L2LTA4HMAOBTAAR1 | |
| SCHEMBL7973439 | 0.87 | KEAP1 (0.67) | KEAP1NFE2L2LTA4HMAOBST14 | |
| Hydrochloric Acid SCHEMBL6573053 | 0.85 | LTA4H (0.62) | KEAP1NFE2L2LTA4HMAOBTAAR1 | |
| SCHEMBL23798500 | 0.85 | APP (0.49) | KEAP1NFE2L2LTA4HAPPTAAR1 | |
| SCHEMBL23799321 | 0.85 | LTA4H (0.49) | LTA4HAPPTAAR1PLA2G2A | |
| SCHEMBL26659483 | 0.85 | KEAP1 (0.56) | KEAP1NFE2L2APPMAOB | |
| Hydrochloric Acid SCHEMBL26601051 | 0.83 | MAOB (0.54) | KEAP1NFE2L2APPMAOB | |
| SCHEMBL25975862 | 0.82 | KEAP1 (0.58) | KEAP1NFE2L2APPMAOBST14 | |
| SCHEMBL1263392 | 0.82 | LTA4H (0.46) | LTA4HAPPMAOBTAAR1PLA2G2A | |
| SCHEMBL20128987 | 0.82 | TSHR (0.50) | LTA4HAPPMAOBTAAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773540-B1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC | 2019-10-17 | — | — | US | disclosed |
| WO-2019199532-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC (US) | 2019-10-17 | — | — | WO | disclosed |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | KEAP1 3492/4885NFE2L2 4252/4885LTA4H 1759/4885 |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | KEAP1 3492/4885NFE2L2 4252/4885LTA4H 1759/4885 |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | KEAP1 3492/4885NFE2L2 4252/4885LTA4H 1759/4885 |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | KEAP1 3492/4885NFE2L2 4252/4885LTA4H 1759/4885 |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | KEAP1 3492/4885NFE2L2 4252/4885LTA4H 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.